Exposure–Response Analyses of Ropeginterferon Alfa‐2b in Essential Thrombocythemia
The Journal of Clinical Pharmacology · 2026-10 · 66 (10)
DOI: 10.1002/jcph.70258 ↗Kurz gefasst
Metaanalyse in der Zeitschrift The Journal of Clinical Pharmacology, online erschienen am 29.09.2026. Verfasst von Albert Qin und 20 weiteren Autor:innen. Beteiligte Einrichtung: Medical Research & Clinical Operations, PharmaEssentia Corporation, Taipei 115, Taiwan. Hauptthemen laut MEDLINE: Interferon-alpha, Models, Biological, Polyethylene Glycols, Thrombocythemia, Essential. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: PharmaEssentia Corporation.
Abstract (Originalsprache)
Ropeginterferon alfa‐2b is a new‐generation interferon therapy for the treatment of myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET). This investigation was designed to characterize its population pharmacokinetics–pharmacodynamics (PopPK‐PD) and delineate exposure–response (E‐R) relationships in ET. A population PK model was constructed utilizing aggregated data from five clinical trials, encompassing a study population of Asian and Caucasian patients with ET and healthy volunteers. A sequential modeling strategy was employed to evaluate the PK‐PD with respect to key hematologic markers including platelet and white blood cell counts. Hematologic changes were effectively modeled using sigmoidal indirect‐response models. Individual exposure metrics were subsequently simulated by a target‐mediated drug disposition model and then applied in E‐R analyses for reductions in the allele burden of MPN driver mutations JAK2 V617F and CALR , and safety outcomes. Simulations indicated no significant disparities between ethnicities in ropeginterferon alfa‐2b exposure or the extent of hematologic response. A correlation was observed between drug exposure and a decrease in JAK2 V617F allele burden at 6 and 12 months of treatment. Exposure–safety assessments identified a risk of exposure‐related adverse events, including reversible anemia. Taken together, the data provided a solid PK‐PD framework and insights into the E‐R relationships for ropeginterferon alfa‐2b in the treatment of ET.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Research & Clinical Operations, PharmaEssentia Corporation, Taipei 115, Taiwan.
- Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Pharmaron Clinical Services Co., Ltd, Chengdu, China.
- State Key Laboratory of Experimental Hematology, National Clinical Research Centre for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical Coll…
- The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
- Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong Kong, Hong Kong.
ORCID-Profile: Zhijian Xiao, Brandi N Reeves
Förderung
- PharmaEssentia Corporation
Zitieren
APA
Qin, A., Masarova, L., Chen, H., Xiao, Z., Jin, J., Gill, H., Reeves, B. N., Chaer, F. E., Kirito, K., Komatsu, N., Abu-Zeinah, G., Shimoda, K., Zagrijtschuk, O., Sato, T., Wu, D., Wu, L., Su, X., Gao, Y., Cui, J., …, & Mesa, R. A. (2026). Exposure–Response Analyses of Ropeginterferon Alfa‐2b in Essential Thrombocythemia. The Journal of Clinical Pharmacology, 66(10). https://doi.org/10.1002/jcph.70258
Vancouver
Qin A, Masarova L, Chen H, Xiao Z, Jin J, Gill H, et al. Exposure–Response Analyses of Ropeginterferon Alfa‐2b in Essential Thrombocythemia. The Journal of Clinical Pharmacology. 2026;66(10). doi:10.1002/jcph.70258
BibTeX
@article{Qin2026,
author = {Qin, Albert and Masarova, Lucia and Chen, Haoqi and Xiao, Zhijian and Jin, Jie and Gill, Harinder and Reeves, Brandi N and Chaer, Firas El and Kirito, Keita and Komatsu, Norio and Abu-Zeinah, Ghaith and Shimoda, Kazuya and Zagrijtschuk, Oleh and Sato, Toshiaki and Wu, Daoxiang and Wu, Lei and Su, Xia and Gao, Yucheng and Cui, Jie and Zhang, Lei and Mesa, Ruben A},
title = {Exposure–Response Analyses of Ropeginterferon Alfa‐2b in Essential Thrombocythemia},
journal = {The Journal of Clinical Pharmacology},
year = {2026},
volume = {66},
number = {10},
doi = {10.1002/jcph.70258}
}
EUVIMED